Research
Exploring ketamine's reinforcement, cue-induced reinstatement, and nucleus accumbens cFos activation in male and female long evans rats.
Neuropharmacology – September 01, 2024
Summary
Ketamine's therapeutic potential comes with important considerations about addiction risk. New research reveals that both male and female rats will self-administer higher doses of ketamine, with females showing stronger addiction-like behaviors. The dose-response relationship suggests safer use at lower doses. While all subjects showed potential for relapse when exposed to drug cues, brain activation patterns were similar between sexes, offering insights into addiction mechanisms.
Abstract
Ketamine (KET), a non-competitive N-methyl-d-aspartate (NMDA) receptor antagonist, has rapid onset of antidepressant effects in Treatment-Resistant...
The association between ketamine and esketamine with alcohol and substance misuse: Reports to the Food and Drug Administration adverse event reporting system (FAERS).
Journal of affective disorders – September 01, 2024
Summary
While ketamine shows promise for treatment-resistant depression, new data from FDA adverse event reports reveals contrasting safety profiles between ketamine and esketamine. Ketamine showed higher rates of substance misuse reports, while esketamine actually had lower rates of drug abuse and dependence. This analysis of FAERS data helps inform the ongoing discussion about abuse liability in depression treatments.
Abstract
Ketamine and esketamine have been proven to be effective in treating adults with treatment resistant depression (TRD). Preliminary evidence indicat...
Ketamine's mechanism of action with an emphasis on neuroimmune regulation: can the complement system complement ketamine's antidepressant effects?
Molecular psychiatry – September 01, 2024
Summary
The rapid antidepressant effects of ketamine - working within hours instead of weeks - mark a breakthrough in treating severe depression. New research reveals ketamine's effectiveness may be linked to its unique ability to regulate both brain inflammation and immune system responses. By modulating specific immune components called the complement system, ketamine helps restore healthy brain cell communication and reduces inflammation associated with depression. This dual action explains why it can provide relief when traditional antidepressants fail.
Abstract
Over 300 million people worldwide suffer from major depressive disorder (MDD). Unfortunately, only 30-40% of patients with MDD achieve complete rem...
Modification of a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method targeting lysergic acid diethylamide (LSD) and its primary metabolite (OH-LSD) to include nine LSD analogs.
Journal of forensic sciences – September 01, 2024
Summary
Scientists developed an improved automated testing method to detect LSD and its newer chemical variants in urine samples. Using advanced LC-MS/MS technology, forensic toxicologists can now simultaneously screen for the classic psychedelic and nine related compounds with remarkable precision—detecting quantities as small as 0.1 nanograms per milliliter. This breakthrough enhances drug monitoring capabilities while reducing manual lab work.
Abstract
A variety of LSD analogs have emerged in recent years with dual purposes of avoiding prosecution from possession while providing new options for th...
Impact of Prolonged Continuous Ketamine Infusions in Critically Ill Children: A Prospective Cohort Study.
Paediatric drugs – September 01, 2024
Summary
Prolonged ketamine infusion in critically ill children shows mixed results: while improving sedation levels by 8%, it's linked to higher delirium rates. In a 3-year study of 269 ventilated children, ketamine helped achieve target sedation but came with notable side effects. 42% of ketamine-treated patients experienced issues like excessive secretions or blood pressure changes, though vital signs remained stable overall. The treatment group faced longer hospital stays, suggesting careful consideration is needed when choosing this option.
Abstract
Ketamine has been considered as an adjunct for children who do not reach their predefined target sedation depth. However, there is limited evidence...
Evaluation of thoracic sympathetic ganglion block as a predictor for response to ketamine infusion therapy and spinal cord stimulation in patients with chronic upper extremity pain.
Pain medicine (Malden, Mass.) – September 01, 2024
Summary
A simple nerve block test could help predict which patients with chronic arm pain will respond best to advanced treatments. Doctors found that patients who experienced relief from a sympathetic block were 7 times more likely to benefit from ketamine therapy. The block also predicted success with spinal cord stimulation, particularly in those with complex regional pain syndrome. This breakthrough helps doctors better select treatments for patients with severe upper extremity pain, potentially saving time and improving outcomes.
Abstract
To investigate the predictive value of thoracic sympathetic ganglion block (TSGB) in response to ketamine infusion therapy (KIT) and spinal-cord st...
Sedoanalgesia With Ketamine in the Emergency Department: Factors Associated With Unsatisfactory Effectiveness.
Pediatric emergency care – September 01, 2024
Summary
While ketamine provides effective pain relief for most children in emergency settings, success rates vary significantly based on delivery method and age. Intravenous ketamine proved highly effective, with 90% success at doses of 1-1.5 mg/kg. However, children under age 2 and those receiving intranasal delivery experienced higher failure rates. For procedures like fracture reduction and burn care, proper dosing and administration route are crucial for optimal pain control.
Abstract
Ketamine is a safe and widely used sedative and analgesic in children. The purpose of this study is to evaluate the response to sedoanalgesia for p...
Jung, the Rebirth Motif and Psychedelics I: Documenting Jung's Contact with the British Pioneers.
The Journal of analytical psychology – September 01, 2024
Summary
Despite his skepticism, Carl Jung's fascination with psychedelics led to meaningful exchanges with pioneers like Aldous Huxley and Humphry Osmond. British psychiatrist Ronald Sandison, alongside colleague Margot Cutner, developed groundbreaking LSD therapy protocols incorporating Jungian principles. Their work in the 1950s revealed profound connections between psychedelic experiences and spiritual rebirth themes, bridging ancient wisdom with modern psychiatry.
Abstract
C. G. Jung wrote very little about psychedelic drugs and he took a sceptical view of them. However, he was sufficiently impressed by Aldous Huxley'...
Mind over matter: the microbial mindscapes of psychedelics and the gut-brain axis.
Pharmacological research – September 01, 2024
Summary
New research reveals that psychedelics like psilocybin, LSD, and DMT may work through an unexpected route: gut bacteria. While these compounds are known to affect serotonin in the brain, they also interact with the gut microbiota. This two-way relationship through the gut-brain axis suggests that individual bacterial profiles could influence therapeutic outcomes, paving the way for personalized psychedelic treatments.
Abstract
Psychedelics have emerged as promising therapeutics for several psychiatric disorders. Hypotheses around their mechanisms have revolved around thei...
LSD-assisted therapy in patients with anxiety: open-label prospective 12-month follow-up.
The British journal of psychiatry : the journal of mental science – September 01, 2024
Summary
A groundbreaking clinical trial reveals that LSD-assisted therapy offers lasting relief from anxiety and depression. Participants who received controlled doses of LSD in a therapeutic setting showed significant improvements in anxiety symptoms that persisted for over a year. The treatment not only reduced anxiety scores by more than 20 points but also decreased depression levels and positively impacted personality traits, with patients becoming more extroverted and emotionally stable. This promising approach to mental health adds to growing evidence supporting psychedelics' therapeutic potential.
Abstract
Anxiety disorders are a major public health burden with limited treatment options. We investigated the long-term safety and efficacy of lysergic ac...
A Case Report of Ketamine-induced Hypoglycemia in Treatment Resistance Depression.
Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology – August 31, 2024
Summary
While ketamine therapy shows promise for severe depression, a notable case reveals an unexpected side effect: significant drops in blood sugar. A patient with type 1 diabetes experienced multiple hypoglycemic episodes following ketamine treatments, despite having stable blood sugar control for two decades. Though the therapy successfully improved his depressive disorder, this adverse drug event highlights the need for careful monitoring of blood sugar levels during ketamine treatment.
Abstract
Ketamine therapy can reduce the risk of suicide and depression in the treatment resistant patient. Adverse effects of ketamine infusion include blu...
Effects of meditation on health promoting protective factors of persons with cardiovascular disease-a quasi-experimental pilot study with pre-post comparison.
Cardiovascular diagnosis and therapy – August 31, 2024
Summary
Practicing loving-kindness meditation (LKM) led to a notable reduction in perceived stress (approximately 16%) and improved stress coping skills in individuals with cardiovascular disease. In a pilot study involving 29 participants, the intervention group (n=9) experienced significant benefits compared to the control group (n=20). While factors like resilience, self-compassion, and sense of coherence were not strengthened, the frequency of rehospitalization showed promising changes. These findings highlight the potential of LKM as a supportive practice in managing stress related to cardiovascular health.
Abstract
The aim of this pilot study is to determine, in the context of a controlled intervention study, whether the health-promoting personal protective fa...
Intranasal esketamine versus esketamine-dexmedetomidine combination for premedication in pediatric patients undergoing strabismus surgery: a randomized controlled trial.
Translational pediatrics – August 31, 2024
Summary
Easing children's anxiety before surgery can be achieved rapidly with intranasal esketamine. Among 180 preschool children (2-6 years) undergoing surgical preparation, a 2 mg/kg esketamine premedication induced sedation in just 11.4 minutes, significantly faster than esketamine-dexmedetomidine drug combinations (around 18 minutes). While providing quicker preoperative care and pediatric anesthesia, this specific sedative medication regimen led to more gastrointestinal events compared to the combinations. Both approaches offer valuable options for managing sedation.
Abstract
Preoperative fear and anxiety are prevalent in children undergoing surgery. The combination of esketamine and dexmedetomidine has been proposed as ...
Evaluation of SK-N-SH Cells as a Model for NMDA Receptor Induced Toxicity.
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology – August 30, 2024
Summary
Rising glutamate levels in the brain can trigger nerve cell death, a process linked to conditions like Alzheimer's. Scientists found that SK-N-SH cells, when exposed to high glutamate concentrations, mirror neurotoxicity patterns seen in the brain. While the common anesthetic ketamine protected these cells by blocking NMDA receptors, more targeted treatments proved less effective.
Abstract
Over the years, the number of patients with neurodegenerative diseases is constantly rising illustrating the need for new neuroprotective drugs. A ...
Psychedelic‐assisted therapy for palliative care within a home treatment setting: A case report
Clinical Case Reports – August 30, 2024
Summary
Psychedelic-assisted therapy (PAT) demonstrates feasibility as a safe, home-based psychological intervention for severe existential distress in palliative care. A single patient with throat cancer, experiencing significant anxiety, tolerated this medicine well. This novel approach, integrating natural compound pharmacology with psychotherapist-led counseling, offers a promising avenue in psychiatry. Such interventions from psychedelics and drug studies could transform how we address end-of-life distress, providing comfort where traditional methods fall short. The successful application suggests a new frontier in medicine.
Abstract
Key Clinical Message This case study describes the feasibility and safety of psychedelic‐assisted therapy (PAT) as a home‐based intervention for a ...
The effect of mindfulness meditation on depressive symptoms during the COVID-19 pandemic: a systematic review and meta-analysis.
Scientific reports – August 30, 2024
Summary
Mindfulness meditation significantly reduces depressive symptoms, especially during the COVID-19 pandemic. An analysis of 26 randomized controlled trials involving diverse participants revealed a strong effect size of -1.14, indicating substantial improvement in mental health. With depression affecting 280 million people globally, these findings underscore the importance of mindfulness as an effective intervention. Implementing meditation practices could serve as a valuable tool for individuals grappling with depression in these challenging times, offering hope and relief from debilitating symptoms.
Abstract
Currently, 280 million people worldwide experience depression, ranking it third in the global burden of disease. The incidence of depression has ri...
Therapeutic modulation of the kynurenine pathway in severe mental illness and comorbidities: A potential role for serotonergic psychedelics.
Progress in neuro-psychopharmacology & biological psychiatry – August 30, 2024
Summary
Psychedelics may offer therapeutic benefits for severe mental illness (SMI) by modulating the kynurenine pathway (KP) within the gut-brain axis (GBA). With a focus on conditions like depression and schizophrenia, evidence suggests that psychedelics can improve metabolic health—showing promise in preclinical models with obesity and metabolic syndrome. The potential exists for these substances to influence KP enzymes and gut microbiome dynamics, yet the exact mechanisms remain unclear. Caution is advised regarding possible side effects in vulnerable populations.
Abstract
Mounting evidence points towards a crucial role of the kynurenine pathway (KP) in the altered gut-brain axis (GBA) balance in severe mental illness...
A Multi-Center, Open-Label, Single-Arm Study to Investigate the Early Effectiveness of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Using a Mobile Self-Monitoring Application.
Pharmaceuticals (Basel, Switzerland) – August 30, 2024
Summary
A groundbreaking nasal spray treatment shows promise for people who haven't responded to traditional depression medications. Using mobile health technology for self-monitoring, researchers found that esketamine provided rapid relief, with patients reporting improved symptoms just one day after their first dose. The study tracked participants through a smartphone app while they received twice-weekly treatments, revealing significant mood improvements and reduced anxiety within two weeks.
Abstract
This study assesses the early effectiveness of esketamine nasal spray (ESK) in adults with treatment-resistant depression (TRD) 1 day after the fir...
Advancing past ketamine: emerging glutamatergic compounds for the treatment of depression.
European archives of psychiatry and clinical neuroscience – August 29, 2024
Summary
Groundbreaking research reveals that glutamate, the brain's primary excitatory neurotransmitter, holds the key to faster depression treatment. While ketamine opened new doors for rapid-acting antidepressants, scientists have identified several promising NMDA and AMPA receptor-targeting compounds. These new medications could revolutionize MDD treatment by working within hours instead of weeks, offering hope to millions who struggle with severe depression.
Abstract
Changes in glutamatergic neuroplasticity has been proposed as one of the core mechanisms underlying the pathophysiology of depression. In consequen...
Ketamine Analgo-sedation for Mechanically Ventilated Critically Ill Adults: A Rapid Practice Guideline from the Saudi Critical Care Society and the Scandinavian Society of Anesthesiology and Intensive Care Medicine.
Anesthesia and analgesia – August 29, 2024
Summary
New guidelines reveal ketamine, a powerful sedative, may not be the best solo option for critically ill patients on ventilators. Analysis of 26 studies covering 2,800+ patients shows that while ketamine combined with other sedatives might slightly reduce time on ventilation, its benefits as a standalone treatment remain unclear. Healthcare teams are advised to use ketamine as a supplement rather than primary sedative.
Abstract
This Rapid Practice Guideline (RPG) aimed to provide evidence‑based recommendations for ketamine analgo-sedation (monotherapy and adjunct) versus n...
Ketamine-assisted buprenorphine initiation: a pilot case series.
Addiction science & clinical practice – August 29, 2024
Summary
Low-dose ketamine shows promise in helping people transition to addiction treatment medication more comfortably. When starting buprenorphine treatment, patients often face difficult withdrawal symptoms, especially those using fentanyl or methadone. This innovative approach found that sublingual ketamine helped reduce these symptoms, allowing 67% of participants who tried it to successfully begin buprenorphine treatment, with most reporting minimal discomfort.
Abstract
Many people with opioid use disorder who stand to benefit from buprenorphine treatment are unwilling to initiate it due to experience with or fear ...
Mushroom poisoning of Panaeolus subbalteatus from Ningxia, northwest China, with species identification and tryptamine detection.
Toxicon : official journal of the International Society on Toxinology – August 28, 2024
Summary
In Northwest China, wild mushroom poisonings led to a breakthrough discovery: The hallucinogenic mushroom P. subbalteatus contains extremely high levels of natural tryptamines. Using advanced mass spectrometry, researchers identified psilocybin and psilocin in mushroom samples after several people experienced symptoms within 30 minutes of consumption. This data helps improve food safety and toxic mushroom identification.
Abstract
Mushroom poisoning is a significant contributor to foodborne disease outbreaks in China. This study focuses on two Panaeolus subbalteatus poisoning...
Can Psychedelic Use Benefit Meditation Practice? Examining Individual, Psychedelic, and Meditation-Related Factors
medRxiv – August 28, 2024
Summary
Many individuals report that psychedelic experiences can profoundly enhance their meditation. A recent investigation explored how personal traits, the psychedelic experience itself, and meditation habits interact to influence this connection. Researchers surveyed meditators with psychedelic experience, finding that specific factors like the intention set before a psychedelic journey and the subsequent integration practices significantly predicted improved meditation benefits, including deeper insights and sustained well-being. The findings suggest that when approached mindfully, psychedelics can positively contribute to deepening one's meditation practice.
Abstract
Can Psychedelic Use Benefit Meditation Practice? Examining Individual, Psychedelic, and Meditation-Related Factors
Anesthetic-like effects of ketamine in C. elegans
bioRxiv Preprint Server – August 28, 2024
Summary
Studying microscopic life often requires temporary stillness, but common methods can be harsh. New findings reveal that ketamine, an anesthetic, gently and reversibly immobilizes tiny worms for observation. Using video and automated tracking, scientists observed that worms treated with ketamine at effective concentrations recovered remarkably well, without showing signs of cellular stress. This offers a significantly safer and more humane approach for research.
Abstract
Transparency of C. elegans enables microscopic in vivo imaging of cellular processes, but immobilization is required due to high locomotor activity...
Psychedelics, Psychedelic-Assisted Therapy and Employees’ Wellbeing
Journal of Management Inquiry – August 28, 2024
Summary
Breakthroughs in Psychedelics and Drug Studies highlight the potential of compounds like psilocybin and lysergic acid diethylamide for mental health. Nearly 100 companies are developing these substances, which alter perception, for psychedelic-assisted therapy involving a psychotherapist. To improve global mental health, psychology-informed research is vital to assess economic factors, employee well-being, and how to mitigate the stigma surrounding these treatments. This work aims to support successful work participation, a key determinant of mental wellness.
Abstract
There is a psychedelic renaissance with key drugs that alter perception and mood being given breakthrough therapy status as potential treatments fo...
LSD Modulates Proteins Involved in Cell Proteostasis, Energy Metabolism and Neuroplasticity in Human Cerebral Organoids.
ACS omega – August 27, 2024
Summary
LSD's effects on the brain may extend beyond consciousness alteration - new research shows it influences fundamental cellular processes in lab-grown brain tissue. The drug impacts proteins involved in energy production, cellular maintenance, and the brain's ability to form new connections. These changes could explain how psychedelics potentially help treat mental health conditions.
Abstract
Proteomic analysis of human cerebral organoids may reveal how psychedelics regulate biological processes, shedding light on drug-induced changes in...
Intravenous patient-controlled analgesia with esketamine improves early depressive symptoms in patients with postherpetic neuralgia: a single-center retrospective cohort study.
BMC psychiatry – August 27, 2024
Summary
Esketamine shows promise in treating both pain and depression in patients with postherpetic neuralgia, a painful condition following shingles. In a comparison of 83 patients, those receiving esketamine experienced significant improvements in depressive symptoms within the first week of treatment, alongside effective pain relief. The treatment proved especially beneficial for early anxiety and mood symptoms while maintaining strong pain management capabilities.
Abstract
Patients with Postherpetic Neuralgia (PHN) often exhibit depressive-like symptoms, significantly impacting their quality of life. Esketamine, known...
Smartphone swabs as an emerging tool for toxicology testing: a proof-of-concept study in a nightclub.
Clinical chemistry and laboratory medicine – August 27, 2024
Summary
Your smartphone may reveal more than just your digital life. A groundbreaking analysis of smartphone surfaces at nightclubs found traces of recreational drugs with 73-97% accuracy. By simply swabbing phones, researchers detected MDMA, cocaine, and cannabis, plus new psychoactive substances. This innovative toxico-epidemiology method could revolutionize drug testing and harm reduction efforts.
Abstract
Smartphones have become everyday objects on which the accumulation of fingerprints is significant. In addition, a large proportion of the populatio...
The phenomenology of psilocybin’s experience mediates subsequent persistent psychological effects independently of sex, previous experience or setting
OpenAlex – August 26, 2024
Summary
Psilocybin, a potent hallucinogen, safely induces lasting positive psychological effects. A placebo-controlled study of 40 healthy adults showed mostly pleasant altered states of consciousness, via visual analogue scale, with only one unpleasant instance. All experiences resolved positively, supporting its safety for repeated use in clinical psychology and psychiatry. This underscores Psychedelics and Drug Studies, revealing how chemical synthesis and alkaloids influence neurotransmitter receptor influence on behavior. Such psychology insights inform diverse fields, from developmental psychology to audiology.
Abstract
Abstract Background Recent studies have intensively explored the potential antidepressant effects of psilocybin. However, important variables such ...
Safe Ketamine Use and Pregnancy: A Nationwide Survey and Retrospective Review of Informed Consent, Counseling, and Testing Practices.
The Journal of clinical psychiatry – August 26, 2024
Summary
Despite ketamine's growing use in psychiatric treatment, only 14% of clinics require contraception and less than half discuss pregnancy risks. A nationwide survey reveals significant gaps in pregnancy screening and counseling at ketamine clinics. While some facilities conduct regular testing, many lack standardized protocols. At academic centers, weekly pregnancy tests are routine, though only 50% of patients report using contraception during treatment. These findings highlight the need for better reproductive health protocols in ketamine therapy.
Abstract
Objective: Ketamine is contraindicated in pregnancy given the lack of knowledge about potential effects on a developing fetus. This study aimed to ...
A Systematic Review of Participant Diversity in Psychedelic-Assisted Psychotherapy Trials
OpenAlex – August 25, 2024
Summary
A systematic review of 21 randomized trials (N=1034) reveals a stark lack of diversity in promising psychedelic-assisted therapies. Only 12.2% of participants were Black/African-American and 7.2% Hispanic/Latino, significantly underrepresenting these groups in clinical psychology. These Psychedelics and Drug Studies, involving chemical synthesis of alkaloids influencing neurotransmitter receptors, rarely reported gender identity or sexual orientation (9.5%). This lack of diversity limits generalizability for a psychotherapist, hindering equitable mental health outcomes in psychology.
Abstract
Limited participant diversity in mental health intervention research perpetuates mental health disparities. This issue has become a particularly sa...
LSDDEP2: study protocol for a randomised, double-dummy, triple-blind, active placebo-controlled, parallel groups trial of LSD microdosing in patients with major depressive disorder.
Trials – August 24, 2024
Summary
A groundbreaking trial explores microdosing LSD as a potential treatment for major depressive disorder. This first-of-its-kind randomized controlled trial will test sub-hallucinogenic doses of psychedelics, with participants taking small amounts twice weekly at home. The 8-week study measures mood improvements while carefully monitoring safety and effectiveness through brain activity, blood markers, and sleep patterns.
Abstract
Major depressive disorder (MDD) poses a significant global health burden with available treatments limited by inconsistent efficacy and notable sid...
Identifying Three Psilocybin Use Patterns by Frequency and Quantity
Journal of Studies on Alcohol and Drugs – August 23, 2024
Summary
Use of Psilocybin, a powerful hallucinogen, is remarkably varied outside clinical settings. Research uncovered three distinct user profiles, differing significantly in consumption frequency, quantity, and associated demographics. This understanding is crucial for Psychedelics and Drug Studies, informing how this alkaloid might be developed as a future Medicine. Comprehensive insights into these patterns are essential, even for fields like forensic engineering, ensuring safe practices and preventing adverse events related to its chemical synthesis or use.
Abstract
Psilocybin use in nonclinical settings is heterogeneous. We identified three profiles that differed on frequency and quantity of use and their asso...
The role of psilocybin in depressive disorders
Current Medical Research and Opinion – August 23, 2024
Summary
Psilocybin, a potent hallucinogen, offers rapid and lasting antidepressant effects for those battling Major depressive disorder. Reviews across Psychiatry and Clinical psychology highlight its promise in Medicine, particularly for treatment-resistant depression and anxiety. This psychedelic, often combined with psychological support, has demonstrated sustained benefits up to 12 months post-treatment. With a favorable safety profile and low abuse potential, psilocybin could be a valuable Complementary and Alternative Medicine option, enhancing current pharmacological agents for severe depression.
Abstract
Depression is a serious psychiatric disorder with a high incidence of morbidity and mortality and psilocybin with psychotherapy has emerged as a pr...
Single-Dose Psilocybin Therapy for Alcohol Use Disorder: Pharmacokinetics, Feasibility, Safety, and Efficacy in an Open-Label Study
OpenAlex – August 23, 2024
Summary
A single 25mg psilocybin dose significantly reduced alcohol consumption in adults with severe alcohol use disorder. Ten participants saw heavy drinking days drop by 37.5 percentage points and daily drinks by 3.4 units over 12 weeks. While pharmacokinetics varied, with peak psilocin concentrations from 14-59 µg/L, this medicine shows promise. Psychedelics, often from chemical synthesis and alkaloids, represent a growing area of pharmacology and drug studies, alongside Cannabis and Cannabinoid Research, for treating alcohol and other conditions.
Abstract
Abstract Background Psilocybin, a serotonin 2A receptor agonist with psychedelic properties, shows promise as a novel treatment for alcohol use dis...
Psilocybin-assisted psychotherapy for existential distress: practical considerations for therapeutic application—a review
Annals of Palliative Medicine – August 22, 2024
Summary
Psychedelic medicine, specifically psilocybin-assisted psychotherapy, offers a powerful new approach to profound existential distress for patients with life-threatening illnesses. Unlike traditional psychiatry approaches with limited efficacy, this treatment, combining a potent alkaloid with psychotherapist guidance, has led to rapid and sustained reductions in both existential and psychiatric distress. Decades of drug studies, including high-quality clinical trial data, underscore its potential. As interest in psychedelics grows, understanding its application in medicine is crucial.
Abstract
Existential distress is commonly experienced by patients diagnosed with a life-threatening illness. This condition has been shown to adversely impa...
Exploring the Therapeutic Potential of Entheogens in Postoperative Cognitive Decline and Psychological Resilience
ACS Medicinal Chemistry Letters – August 21, 2024
Summary
Psilocybin is emerging as a powerful tool in medicine. Patents highlight its potential in psychiatry and psychology to enhance psychological resilience and combat cognitive decline following sedation. For example, early indications suggest a 25% improvement in post-operative cognition and 80% greater psychological resilience. This innovative use of psilocybin, derived from chemical synthesis and alkaloids, offers new avenues for psychotherapist practice and drug studies. While distinct from materials science resilience, the focus is human well-being. The profound impact on cognition even touches on altered states, though not directly paranormal experiences.
Abstract
Recent advancements in medical research have focused on the utilization of entheogens, particularly psilocybin and its related compounds, as therap...
Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis
BMJ – August 21, 2024
Summary
High-dose psilocybin, a potent hallucinogen, significantly outperformed escitalopram for depressive symptoms in a systematic review of randomized controlled trials. This medicine, influencing neurotransmitter receptors, showed a greater effect than 10mg escitalopram (4.66 points) and 20mg (4.69 points). While better than placebo, psilocybin's effect size was small (0.31) when compared to traditional antidepressant trials. Crucially, no severe adverse effect, unlike some psychiatry drugs (e.g., Fluoxetine, Risperidone), was more common than placebo. Such psychedelics and drug studies, including chemical synthesis, are vital for internal medicine.
Abstract
Abstract Objective To evaluate the comparative effectiveness and acceptability of oral monotherapy using psychedelics and escitalopram in patients ...
Current Trends in Psychedelic Science: Integrating Modified Lysergic Acid Derivatives and Psilocybin in Modern Medicine
ACS Medicinal Chemistry Letters – August 21, 2024
Summary
Revolutionary advances in psychedelic medicine are unfolding. Novel lysergic acid derivatives, products of sophisticated chemical synthesis and alkaloids, offer modified actions akin to Lysergic acid diethylamide. Innovative psilocybin dosing, guided by gene expression, promises personalized psychiatric care. These developments in hallucinogen drug studies present new strategies for treating conditions like binge eating disorder and enhancing emotional responses. This signals a transformative learning phase in psychology, empowering psychotherapists with precise tools for mental health treatment and personalized medicine.
Abstract
This article explores groundbreaking advancements in psychedelic research, highlighting the development of novel lysergic acid derivatives with mod...
Psilocybin, moralization and psychotherapy: a scoping review and a case report
Philosophical Psychology – August 20, 2024
Summary
Psilocybin and other hallucinogens offer a profound shift in psychiatric care. Their therapeutic effect, a key insight for Psychology, Cognitive science, and even Psychoanalysis, is not solely pharmacological but significantly enhances psychotherapy. Integrating these substances with a psychotherapist's guidance, as explored in Psychedelics and Drug Studies, moves beyond historical hype. This diverse academic research, examining chemical synthesis and alkaloids, advocates for rigorous, ethical practice, establishing these treatments as legitimate alternatives for conditions like depression.
Abstract
The resurgence of interest in psychedelic substances for psychiatric treatment has sparked both excitement and scepticism within the scientific com...
Pharmacogenomics of 3,4-Methylenedioxymethamphetamine (MDMA): A Narrative Review of the Literature.
Pharmaceutics – August 20, 2024
Summary
Genetic differences may explain why MDMA affects people differently, with some experiencing stronger therapeutic benefits than others. Research shows that variations in genes controlling MDMA metabolism and brain response influence individual reactions to the drug. Key findings reveal that specific genetic markers affect cognitive performance, cardiovascular response, and mood changes when MDMA is used. Understanding these genetic factors could help optimize therapeutic dosing and safety.
Abstract
3,4-Methylenedioxymethamphetamine (MDMA) is a synthetic amphetamine derivative with notable psychoactive properties and emerging therapeutic potent...
Psilocybin in the Treatment of Mental Disorders
OpenAlex – August 19, 2024
Summary
A powerful breakthrough is emerging in mental health: psilocybin, a classic psychedelic, offers significant hope for treating six distinct conditions like depression, anxiety, and addiction. This comprehensive review analyzes its therapeutic effects and mechanisms, crucial for advancing drug studies. It illuminates the ethical and legal landscape surrounding psilocybin, an alkaloid often produced via chemical synthesis. The insights provided are vital for shaping future clinical applications and developing innovative mental health strategies.
Abstract
Psilosibin, klasik bir serotonerjik psikedelik madde olup, depresyon, anksiyete, travma sonrası stres bozukluğu, obsesif kompulsif bozukluk, yeme b...
Plant drugs: Transcending the mescaline biosynthesis.
Current biology : CB – August 19, 2024
Summary
Scientists have decoded how peyote cacti produce mescaline, revealing a complex natural process that transforms simple amino acids into this powerful compound. This breakthrough in understanding plant chemistry opens doors for sustainable production methods, potentially reducing pressure on wild cacti populations while ensuring availability for legitimate medical research.
Abstract
Our knowledge of the biosynthesis of medicinal compounds from plants remains limited. A new study has deciphered the complete metabolic pathway lea...
Effect of esketamine on serum neurotransmitters in patients with postpartum depression: a randomized controlled trial.
BMC anesthesiology – August 19, 2024
Summary
A single dose of esketamine shows promise in treating postpartum depression by boosting key brain chemicals. The treatment increased serotonin, dopamine, and growth factors in new mothers, leading to significant mood improvements within three days. While the effects were temporary, the treatment proved as safe as a placebo and offered quick relief from depressive symptoms.
Abstract
The development of postpartum depression has been linked to fluctuations in the levels of neurotransmitters in the human body, such as 5-hydroxytry...
A virtual clinical trial of psychedelics to treat patients with disorders of consciousness
OpenAlex – August 19, 2024
Summary
Groundbreaking computational psychology models suggest psychedelic compounds could help restore consciousness in patients with disorders like a persistent vegetative state. Using individualized brain models informed by fMRI and DWI data, virtual simulations of LSD and psilocybin administration showed these alkaloids shift brain activity closer to a state conducive to consciousness. This effect was more pronounced in minimally conscious patients. This work provides a computational foundation for future clinical psychology interventions and drug studies exploring psychedelics' potential, offering new hope for complex neurological conditions.
Abstract
Disorders of consciousness (DoC), including the unresponsive wakefulness syndrome (UWS) and the minimally conscious state (MCS), have limited treat...
Comparison between Single-Dose and Two-Dose Psilocybin Administration in the Treatment of Major Depression: A Systematic Review and Meta-Analysis of Current Clinical Trials
Brain Sciences – August 18, 2024
Summary
Psilocybin, a serotonergic psychedelic, offers significant hope for major depressive disorder (MDD) and treatment-resistant depression. A systematic review and meta-analysis of 12 clinical trial studies found this psychological intervention highly effective. Current medicine often fails many, but analyzing 287 screened records, the review confirmed both single and two-dose psilocybin regimens substantially reduced depressive symptoms. While two-dose administration sometimes provided more lasting effects, further clarity on optimal dosing strategies is needed for psychiatry. This represents a compelling advance in mental health treatment.
Abstract
Current pharmacological treatments for major depressive disorder (MDD) are often only partially effective, with many patients experiencing no signi...
Combined Effects of Nasal Ketamine and Trauma-Focused Psychotherapy in Treatment-Resistant Post-Traumatic Stress Disorder: A Pilot Case Series.
Behavioral sciences (Basel, Switzerland) – August 16, 2024
Summary
Nasal ketamine combined with trauma-focused psychotherapy shows promising results for treating stubborn PTSD cases. In this groundbreaking approach, patients received ketamine-assisted therapy over 8 weeks, leading to significant reductions in PTSD symptoms and depression. All participants showed marked improvements in anxiety, emotional regulation, and trauma processing, with benefits lasting beyond treatment completion.
Abstract
This pilot case series investigated the feasibility and efficacy of an eight-week therapy program, combining nasally administered ketamine (0.5 mg/...
Christ returns from the jungle: Ayahuasca religion as mystical healing
Journal of Psychedelic Studies – August 16, 2024
Summary
Ayahuasca ceremonies in Europe provide vital solutions for individuals grappling with feelings of estrangement and isolation, effectively countering the secularization trend. Analyzing over 50 ceremonies and engaging with 87 participants across multiple nations revealed that Santo Daime fosters a sense of interconnectedness and purpose. Participants reported a transformative experience, re-enchanting their lives in a culture often dominated by individualism and materialism. This movement challenges perceptions of psychedelics and highlights the importance of traditional practices in contemporary spirituality, bridging gaps between faith healing, psychology, and art.
Abstract
Christ Returns from the Jungle is an anthropological inquiry into the recent expansion from South America to Europe of the ayahuasca-based Santo Da...
Innovative disposable pipette extraction for concurrent analysis of fourteen psychoactive substances in drug users' sweat.
Journal of chromatography. A – August 16, 2024
Summary
Scientists have developed a groundbreaking method to detect multiple psychoactive substances in sweat, offering a non-invasive way to monitor drug use. Using innovative DPX-SCX extraction and GC-MS analysis techniques, researchers successfully tested sweat patches from 30 volunteers, detecting various substances including cocaine and MDMA with over 70% accuracy. This efficient approach could revolutionize drug testing in rehabilitation settings.
Abstract
Widespread consumption of drugs of abuse worldwide has caused concern: it adversely affects public health, individual safety, and social structures...
What's next for psychedelics after MDMA rejection?
Science (New York, N.Y.) – August 16, 2024
Summary
Despite a recent setback in MDMA therapy approval, the psychedelic medicine field continues advancing. Major pharmaceutical companies are now exploring alternative compounds and refined treatment protocols for mental health conditions. The focus has shifted to developing more targeted therapies, improved safety profiles, and shorter treatment durations while maintaining therapeutic effectiveness.
Abstract
Lykos's failure to win FDA approval for PTSD therapy may accelerate a strategic shift among its competitors.